Extending the survival of HR+ breast cancer patients receiving CDK4/6 inhibitors by targeting IL17-producing gamma delta T cells Grant uri icon

Overview

date/time interval

  • August 1, 2022 - July 31, 2026

sponsor award ID

  • W81XWH-22-1-0506

Affiliation